At ManRos Therapeutics we are currently developing leucettines as DYRK1A inhibitory drug candidates [6,7,42,43] to address cognitive deficits associated with DS [Nguyen et al., in preparation] and AD [44,45], but applications in cancer, inflammation and diabetes treatment should be investigated, too. The gene discussed is DYRK1A; the disease is cancer.